The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 164:1214-1220, August 2007
doi: 10.1176/appi.ajp.2007.06111886
© 2007 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Newport, D. J.
* Articles by Stowe, Z. N.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Newport, D. J.
* Articles by Stowe, Z. N.
Related Collections
* Gender
* Atypical Neuroleptics

Atypical Antipsychotic Administration During Late Pregnancy: Placental Passage and Obstetrical Outcomes

D. Jeffrey Newport, M.D., Martha R. Calamaras, B.S., C. Lindsay DeVane, Pharm.D., Jennifer Donovan, Ph.D., Aquila J. Beach, B.S., Stephanie Winn, M.D., Bettina T. Knight, B.S.N., R.N., Bryan B. Gibson, B.S., Adele C. Viguera, M.D., Michael J. Owens, Ph.D., Charles B. Nemeroff, M.D., Ph.D., and Zachary N. Stowe, M.D.

OBJECTIVES: There are limited data regarding the use of atypical antipsychotic medications in pregnancy. The objectives of the current study were to quantify placental permeability to antipsychotic medications and to document obstetrical outcomes for women taking these agents proximate to delivery. METHOD: The authors conducted a prospective observational study of women treated with an atypical antipsychotic or haloperidol during pregnancy. Maternal and umbilical cord plasma samples collected at delivery were analyzed for medication concentrations. Placental passage was defined as the ratio of umbilical cord to maternal plasma concentrations (ng/ml). Obstetrical outcome was ascertained through maternal reports and reviews of obstetrical records. RESULTS: Fifty-four pregnant women with laboratory-confirmed antipsychotic use proximate to delivery were included in the analysis. Complete maternal-infant sample pairs were available for 50 participants. Placental passage ratio was highest for olanzapine (mean=72.1%, SD=42.0%), followed by haloperidol (mean=65.5%, SD=40.3%), risperidone (mean=49.2%, SD=33.9%), and quetiapine (mean=23.8%, SD=11.0%). There were tendencies toward higher rates of low birth weight (30.8%) and neonatal intensive care unit admission (30.8%) among neonates exposed to olanzapine. CONCLUSIONS: All four antipsychotics demonstrated incomplete placental passage. Quetiapine demonstrated the lowest placental passage of the medications studied. These novel data provide an initial quantification of the placental passage of antipsychotics and fetal exposure in humans, demonstrating significant differences between individual medications.




This article has been cited by other articles:


Home page
JWatch PsychiatryHome page
Psychiatric Medications, Psychiatric Disorders, and Pregnancy: New Data
Journal Watch Psychiatry, October 1, 2007; 2007(1001): 1 - 1.
[Full Text]




Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org